

Brian K Link

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/40285/publications.pdf>

Version: 2024-02-01

256
papers

14,769
citations

23565

58
h-index

21539

114
g-index

259
all docs

259
docs citations

259
times ranked

15989
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-cell analysis of SÅ©zary syndrome reveals novel markers andÂshifting gene profiles associated with treatment. Blood Advances, 2023, 7, 321-335.	5.2	7
2	Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Advances, 2022, 6, 1350-1360.	5.2	9
3	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. Blood Advances, 2022, 6, 2745-2756.	5.2	3
4	An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma. Blood Advances, 2022, 6, 2035-2044.	5.2	12
5	Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematology, the, 2022, 9, e289-e300.	4.6	24
6	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL). HemaSphere, 2022, 6, e745.	2.7	7
7	Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood Advances, 2022, 6, 5210-5221.	5.2	2
8	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL. Leukemia, 2021, 35, 522-533.	7.2	28
9	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. , 2021, 5, 200-217.		0
10	The significance of gradient expression of chromosome region maintenance protein 1 (exportin1) in large cell lymphoma. Haematologica, 2021, 106, 2261-2264.	3.5	0
11	Impact of Organ FunctionÂ€Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?. Journal of Clinical Oncology, 2021, 39, 1641-1649.	1.6	16
12	Body mass index and survival of patients with lymphoma. Leukemia and Lymphoma, 2021, 62, 2671-2678.	1.3	5
13	Surveillance imaging during first remission in follicular lymphoma does not impact overall survival. Cancer, 2021, 127, 3390-3402.	4.1	6
14	Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer Journal, 2021, 11, 133.	6.2	4
15	Lack of intrafollicular memory CD4Â€+Â€T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma. Blood Cancer Journal, 2021, 11, 130.	6.2	27
16	Paraneoplastic erythema annulare centrifugum associated with mycosis fungoides. JAAD Case Reports, 2021, 17, 65-68.	0.8	1
17	Follicular Lymphoma Tumor-Cell Transcriptional Programs Associate with Distinct Somatic Alterations and Tumor-Immune Microenvironments. Blood, 2021, 138, 1327-1327.	1.4	0
18	A Retrospective Cohort Study of Treatment Outcomes of Adult Patients with Relapsed or Refractory Low-Grade Follicular Lymphoma (ReCORD-FL). Blood, 2021, 138, 1349-1349.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Efficacy Comparison of Tisagenlecleucel Versus Standard of Care in Patients with Relapsed or Refractory Follicular Lymphoma. <i>Blood</i> , 2021, 138, 3528-3528.	1.4	3
20	Trial-in-Progress: Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma (NCT#03269669): SWOG S1608. <i>Blood</i> , 2021, 138, 2425-2425.	1.4	0
21	Event-Free Survival at 24 Months (EFS24) Becomes an Important Clinical Endpoint in Newly Diagnosed Mantle Cell Lymphoma in the New Era. <i>Blood</i> , 2021, 138, 2429-2429.	1.4	1
22	Event-Free and Overall Survival in over 6,000 Patients Treated with Frontline Immunochemotherapy for Follicular Lymphoma between 2002-2018: First Report from the International FLIPI24 Consortium. <i>Blood</i> , 2021, 138, 3527-3527.	1.4	1
23	Evaluation of Eligibility Criteria in First-Line Clinical Trials for Follicular Lymphoma: A MER/LEO Database Analysis. <i>Blood</i> , 2021, 138, 338-338.	1.4	0
24	Integration of Tumor Transcriptomic, Genomic, and Immune Profiles Reveals Distinct Populations of Low-Grade B-Cell Lymphomas with Poor Outcome. <i>Blood</i> , 2021, 138, 808-808.	1.4	0
25	Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R. <i>Blood</i> , 2021, 138, 453-453.	1.4	0
26	Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2020, 71, 1221-1228.	5.8	22
27	Compliance with cancer screening and influenza vaccination guidelines in non-Hodgkin lymphoma survivors. <i>Journal of Cancer Survivorship</i> , 2020, 14, 316-321.	2.9	5
28	Trends of lymphoma incidence in US veterans with rheumatoid arthritis, 2002â€“2017. <i>RMD Open</i> , 2020, 6, e001241.	3.8	4
29	Somatic copy number gains in MYC, BCL2, and BCL6 identifies a subset of aggressive alternative-DH/TH DLBCL patients. <i>Blood Cancer Journal</i> , 2020, 10, 117.	6.2	18
30	Prevalence and the impact of hypogammaglobulinemia in newly diagnosed chronic lymphocytic lymphoma patients. <i>EJHaem</i> , 2020, 1, 537-544.	1.0	2
31	Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 2519-2529.	1.6	93
32	Foreseeing what is to happen in DLBCL. <i>Blood</i> , 2020, 135, 2014-2015.	1.4	4
33	Immunologic dysfunction and Hodgkin lymphoma: Insight to better therapy?. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 780-781.	2.9	0
34	CD20+ cutaneous T-cell lymphoma with phenotypic shift after treatment with rituximab: Case report and review of the literature. <i>JAAD Case Reports</i> , 2020, 6, 308-310.	0.8	5
35	Estimates and Timing of Therapy Initiation during the First Decade for Patients with Follicular Lymphoma Who Were Observed at Diagnosis. <i>Blood</i> , 2020, 136, 7-8.	1.4	2
36	Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis. <i>Blood</i> , 2020, 136, 35-36.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Outcomes of Patients with Limited-Stage Plasmablastic Lymphoma. <i>Blood</i> , 2020, 136, 15-16.	1.4	0
38	Global Transcriptional States of Follicular Lymphoma B Cells Highlight Distinct Groups of Tumor Identity Associated with Somatic Alterations and Tumor Microenvironment. <i>Blood</i> , 2020, 136, 21-22.	1.4	0
39	Body Mass Index and Survival of Patients with Lymphoma. <i>Blood</i> , 2020, 136, 2-3.	1.4	0
40	Causes of Death in Non-Follicular Indolent B-Cell Lymphoma in the Rituximab Era. <i>Blood</i> , 2020, 136, 36-37.	1.4	0
41	The Expression of Chromosome Region Maintenance Protein 1 (CRM1) in Large Cell Lymphoma. <i>Blood</i> , 2020, 136, 39-40.	1.4	0
42	Clonal Somatic Mutations Are a Biomarker for Inferior Prognosis in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 26-27.	1.4	1
43	Beyond Mortality: Health-Related Quality of Life in Adolescent and Young Adult Patients with Lymphoma: A Longitudinal Study. <i>Blood</i> , 2020, 136, 7-8.	1.4	0
44	Quality of Life after Diagnosis in Survivors of Aggressive Lymphomas. <i>Blood</i> , 2020, 136, 15-16.	1.4	0
45	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. <i>Genetic Epidemiology</i> , 2019, 43, 844-863.	1.3	28
46	Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. <i>Blood</i> , 2019, 134, 1289-1297.	1.4	26
47	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	6.2	37
48	Single-Cell Profiling of Cutaneous T-Cell Lymphoma Reveals Underlying Heterogeneity Associated with Disease Progression. <i>Clinical Cancer Research</i> , 2019, 25, 2996-3005.	7.0	80
49	Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2019, 37, 1819-1827.	1.6	44
50	Recurrent MSCE116K mutations in ALK-negative anaplastic large cell lymphoma. <i>Blood</i> , 2019, 133, 2776-2789.	1.4	55
51	Host genetic variation in tumor necrosis factor and nuclear factor- κ B pathways and overall survival in mantle cell lymphoma: A discovery and replication study. <i>American Journal of Hematology</i> , 2019, 94, E153-E155.	4.1	1
52	The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non-follicular indolent B-cell lymphomas. <i>American Journal of Hematology</i> , 2019, 94, 658-666.	4.1	19
53	Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts. <i>Journal of Clinical Oncology</i> , 2019, 37, 144-152.	1.6	142
54	<p>Pretreatment Hemoglobin Adds Prognostic Information To The NCCN-IPI In Patients With Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Containing Chemotherapy</p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 987-996.	3.0	5

#	ARTICLE	IF	CITATIONS
55	Maintenance rituximab or observation after frontline treatment with bendamustine+rituximab for follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 184, 524-535.	2.5	27
56	Prevalence, clinical characteristics and prognosis of EBV+positive follicular lymphoma. <i>American Journal of Hematology</i> , 2019, 94, E62-E64.	4.1	15
57	Novel treatment approaches and future perspectives in follicular lymphoma. <i>Therapeutic Advances in Hematology</i> , 2019, 10, 204062071882051.	2.5	11
58	Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. <i>Lancet, The</i> , 2019, 393, 229-240.	13.7	517
59	Second-line and subsequent therapy and outcomes for follicular lymphoma in the United States: data from the observational National LymphoCare Study. <i>British Journal of Haematology</i> , 2019, 184, 660-663.	2.5	51
60	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. <i>Frontiers in Oncology</i> , 2019, 9, 1539.	2.8	6
61	Integration of Genetic, Transcriptomic, and Immune Profiles Reveals Genomically-Distinct Populations in Low-Grade Lymphomas. <i>Blood</i> , 2019, 134, 2764-2764.	1.4	0
62	A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. <i>Lancet Oncology, The</i> , 2018, 19, 549-561.	10.7	165
63	Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. <i>European Journal of Cancer</i> , 2018, 93, 57-68.	2.8	90
64	A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy. <i>Blood</i> , 2018, 132, 49-58.	1.4	130
65	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , 2018, 24, 679-690.	30.7	1,224
66	A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <i>MYC</i> predicts patient outcome in two independent cohorts. <i>British Journal of Haematology</i> , 2018, 180, 286-290.	2.5	13
67	Variability of performance status assessment between patients with hematologic malignancies and their physicians. <i>Leukemia and Lymphoma</i> , 2018, 59, 695-701.	1.3	11
68	Updating survival estimates in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) based on treatment-free interval length. <i>Leukemia and Lymphoma</i> , 2018, 59, 643-649.	1.3	14
69	Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era. <i>British Journal of Haematology</i> , 2018, 183, 149-152.	2.5	5
70	Outcomes among North American patients with diffuse large B-cell lymphoma are independent of tumor Epstein-Barr virus positivity or immunosuppression. <i>Haematologica</i> , 2018, 103, 297-303.	3.5	17
71	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
72	Transformation of follicular lymphoma – Why does it happen and can it be prevented?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 49-56.	1.7	6

#	ARTICLE	IF	CITATIONS
73	Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials. <i>Journal of Clinical Oncology</i> , 2018, 36, 1603-1610.	1.6	93
74	Biosimilars: when a negative study can be positive. <i>Lancet Haematology</i> , 2018, 5, e500-e501.	4.6	0
75	Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements. <i>Blood</i> , 2018, 132, 1386-1398.	1.4	97
76	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. <i>Nature Communications</i> , 2018, 9, 4182.	12.8	15
77	Primary diffuse large B cell lymphoma of the vulva—Two new cases of a rare entity and review of the literature. <i>JAAD Case Reports</i> , 2018, 4, 962-967.	0.8	5
78	Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. <i>EMBO Journal</i> , 2018, 37, .	7.8	73
79	The association of physical activity before and after lymphoma diagnosis with survival outcomes. <i>American Journal of Hematology</i> , 2018, 93, 1543-1550.	4.1	16
80	Human Pegivirus infection and lymphoma risk and prognosis: a North American study. <i>British Journal of Haematology</i> , 2018, 182, 644-653.	2.5	20
81	Health-related quality of life in patients with cutaneous T-cell lymphoma?. <i>International Journal of Dermatology</i> , 2018, 57, 1314-1319.	1.0	19
82	History of autoimmune conditions and lymphoma prognosis. <i>Blood Cancer Journal</i> , 2018, 8, 73.	6.2	26
83	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. <i>Cancer Research</i> , 2018, 78, 4086-4096.	0.9	34
84	Repeatability and Reproducibility of In Vivo Cone Density Measurements in the Adult Zebrafish Retina. <i>Advances in Experimental Medicine and Biology</i> , 2018, 1074, 151-156.	1.6	4
85	Quality of life at diagnosis predicts overall survival in patients with aggressive lymphoma. <i>Hematological Oncology</i> , 2018, 36, 749-756.	1.7	13
86	Compliance with Age-Appropriate Screening for Malignancies and Influenza Vaccination in 3-Year Lymphoma Survivors. <i>Blood</i> , 2018, 132, 4791-4791.	1.4	0
87	FCGR3A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. <i>Hematological Oncology</i> , 2017, 35, 447-455.	1.7	9
88	Recommendations for Clinical Trial Development in Follicular Lymphoma. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw255.	6.3	23
89	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. <i>Nature Communications</i> , 2017, 8, 14175.	12.8	75
90	Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 703-712.	1.3	3

#	ARTICLE	IF	CITATIONS
91	Primary Breast Lymphoma in the United States: 1975–2013. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	57
92	Associations between elevated pre-treatment serum cytokines and peripheral blood cellular markers of immunosuppression in patients with lymphoma. <i>American Journal of Hematology</i> , 2017, 92, 752-758.	4.1	23
93	Follicular lymphomatoid papulosis with follicular mucinosis: a clinicopathologic study of 3 cases with literature review and conceptual reappraisal. <i>Journal of Cutaneous Pathology</i> , 2017, 44, 360-366.	1.3	10
94	Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study. <i>International Journal of Epidemiology</i> , 2017, 46, 1753-1754i.	1.9	57
95	Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab. <i>American Journal of Hematology</i> , 2017, 92, 1156-1162.	4.1	8
96	Time to Second-line Treatment and Subsequent Relative Survival in Older Patients With Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e11-e25.	0.4	4
97	Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. <i>Blood</i> , 2017, 130, 1800-1808.	1.4	1,084
98	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. <i>Lupus Science and Medicine</i> , 2017, 4, e000187.	2.7	15
99	Incidence of hematologic malignancy and cause-specific mortality in the Women's Health Initiative randomized controlled trial of calcium and vitamin D supplementation. <i>Cancer</i> , 2017, 123, 4168-4177.	4.1	16
100	Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy. <i>British Journal of Haematology</i> , 2017, 179, 50-60.	2.5	49
101	Complement-Regulatory Proteins CFHR1 and CFHR3 and Patient Response to Anti-CD20 Monoclonal Antibody Therapy. <i>Clinical Cancer Research</i> , 2017, 23, 954-961.	7.0	12
102	Early Relapse in Follicular Lymphoma: High Risks and High Stakes. <i>Journal of Oncology Practice</i> , 2017, 13, 810-811.	2.5	1
103	International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 4019-4026.	1.6	50
104	Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 179-184.	4.1	41
105	Will a Better Understanding of the Problem With Transformed Follicular Lymphoma Lead to Better Outcomes?. <i>Journal of Clinical Oncology</i> , 2016, 34, 2566-2567.	1.6	5
106	Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era. <i>British Journal of Haematology</i> , 2016, 172, 724-734.	2.5	44
107	Intravenous immune globulin and thromboembolic adverse events in patients with hematologic malignancy. <i>Blood</i> , 2016, 127, 200-207.	1.4	52
108	Early event status informs subsequent outcome in newly diagnosed follicular lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 1096-1101.	4.1	180

#	ARTICLE	IF	CITATIONS
109	Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. <i>Blood</i> , 2016, 128, 1234-1245.	1.4	105
110	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. <i>Nature Communications</i> , 2016, 7, 10933.	12.8	94
111	Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. <i>American Journal of Hematology</i> , 2016, 91, 770-775.	4.1	22
112	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. <i>Human Molecular Genetics</i> , 2016, 25, 1663-1676.	2.9	52
113	Vitamin D Insufficiency Is Associated with an Increased Risk of Early Clinical Failure in Follicular Lymphoma. <i>Blood</i> , 2016, 128, 1104-1104.	1.4	1
114	Time from Diagnosis to Initiation of Treatment of DLBCL and Implication for Potential Selection Bias in Clinical Trials. <i>Blood</i> , 2016, 128, 3034-3034.	1.4	5
115	Similar Phenotypes Demonstrated upon Initial Diagnosis and at Time of Recurrence in Relapsed DLBCL. <i>Blood</i> , 2016, 128, 5299-5299.	1.4	1
116	Outcomes in refractory aggressive diffuse large b-cell lymphoma (DLBCL): Results from the international SCHOLAR-1 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7516-7516.	1.6	13
117	The oncogenic transcription factor IRF4 is regulated by a novel CD30/NF- κ B positive feedback loop in peripheral T-cell lymphoma. <i>Blood</i> , 2015, 125, 3118-3127.	1.4	68
118	Elevated serum levels of IL-2R, IL-1RA, and CXCL9 are associated with a poor prognosis in follicular lymphoma. <i>Blood</i> , 2015, 125, 992-998.	1.4	47
119	Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). <i>Blood</i> , 2015, 126, 851-857.	1.4	161
120	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv279.	6.3	152
121	Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States. <i>British Journal of Haematology</i> , 2015, 170, 85-95.	2.5	50
122	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. <i>Nature Communications</i> , 2015, 6, 5751.	12.8	58
123	Treatment of diffuse large B-cell lymphoma in the elderly: regimens without anthracyclines are common and not futile. <i>Leukemia and Lymphoma</i> , 2015, 56, 65-71.	1.3	24
124	Reply to V. Pitini et al and L.J. Costa. <i>Journal of Clinical Oncology</i> , 2015, 33, 1625-1626.	1.6	3
125	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2516-2522.	1.6	610
126	Phase 1/2 Study of Ocaratuzumab, an Fc-Engineered Humanized Anti-CD20 Monoclonal Antibody, in Low-Affinity Fc γ R3a Patients with Previously Treated Follicular Lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 42-48.	1.3	29

#	ARTICLE	IF	CITATIONS
127	Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Leukemia and Lymphoma</i> , 2015, 56, 2365-2372.	1.3	2
128	Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2015, 33, 3930-3937.	1.6	24
129	Long-term follow up of rates of secondary malignancy and late relapse of two trials using radioimmunotherapy consolidation following induction chemotherapy for previously untreated indolent lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 2870-2875.	1.3	15
130	Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States. <i>Leukemia and Lymphoma</i> , 2015, 56, 1295-1302.	1.3	22
131	Mutations Targeting the ErbB Pathway and MSC in Peripheral T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 2681-2681.	1.4	4
132	Activity of Idelalisib in High-Risk Follicular Lymphoma with Early Relapse Following Front Line Immunochemotherapy. <i>Blood</i> , 2015, 126, 2744-2744.	1.4	8
133	Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma. <i>Oncotarget</i> , 2015, 6, 9488-9501.	1.8	42
134	Elevated monoclonal and polyclonal serum immunoglobulin free light chain as prognostic factors in B ϵ -and T ϵ cell non ϵ scp>H</scp>odgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 1116-1120.	4.1	16
135	Chemoimmunotherapy for relapsed/refractory and progressive 17p13 ϵ deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low ϵ dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells. <i>American Journal of Hematology</i> , 2014, 89, 757-765.	4.1	32
136	Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein ϵ 10 predicts inferior prognosis in untreated diffuse large B ϵ cell lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 417-422.	4.1	18
137	The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States. <i>Cancer</i> , 2014, 120, 1830-1837.	4.1	33
138	Comparative effectiveness research in follicular lymphoma: current and future perspectives and challenges. <i>Journal of Comparative Effectiveness Research</i> , 2014, 3, 95-107.	1.4	5
139	Genetic polymorphisms in oxidative stress ϵ related genes are associated with outcomes following treatment for aggressive B ϵ cell non ϵ Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2014, 89, 639-645.	4.1	26
140	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. <i>Nature Genetics</i> , 2014, 46, 1233-1238.	21.4	147
141	Genome-wide Association Study Identifies Five Susceptibility Loci for Follicular Lymphoma outside the HLA Region. <i>American Journal of Human Genetics</i> , 2014, 95, 462-471.	6.2	96
142	Active Idiotypic Vaccination Versus Control Immunotherapy for Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 1797-1803.	1.6	75
143	Utility of Routine Post-Therapy Surveillance Imaging in Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 3506-3512.	1.6	144
144	Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. <i>Journal of Clinical Oncology</i> , 2014, 32, 1066-1073.	1.6	304

#	ARTICLE	IF	CITATIONS
145	Event-Free Survival at 12 Months (EFS12) from Diagnosis Is a Robust Endpoint for Disease-Related Survival in Patients with Follicular Lymphoma in the Immunochemotherapy Era. <i>Blood</i> , 2014, 124, 1664-1664.	1.4	8
146	CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1475-1484.	4.2	28
147	Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. <i>Journal of Clinical Oncology</i> , 2013, 31, 3272-3278.	1.6	259
148	Popular mycosis fungoides: report of two patients, literature review, and conceptual reappraisal. <i>Journal of Cutaneous Pathology</i> , 2013, 40, 714-719.	1.3	13
149	Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study. <i>Cancer</i> , 2013, 119, 4129-4136.	4.1	18
150	Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts. <i>Cytokine</i> , 2013, 64, 523-531.	3.2	16
151	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. <i>Nature Genetics</i> , 2013, 45, 868-876.	21.4	179
152	<i>FCGR2A</i> and <i>FCGR3A</i> polymorphisms in classical Hodgkin lymphoma by Epstein-Barr virus status. <i>Leukemia and Lymphoma</i> , 2013, 54, 2571-2573.	1.3	7
153	The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2013, 54, 290-297.	1.3	58
154	Mapping of the <i>IRF8</i> Gene Identifies a 3'UTR Variant Associated with Risk of Chronic Lymphocytic Leukemia but not Other Common Non-Hodgkin Lymphoma Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 461-466.	2.5	13
155	Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6812-6819.	7.0	64
156	A phase I trial of immunostimulatory CpG 7909 oligodeoxynucleotide and ⁹⁰ yttrium ibritumomab tiuxetan radioimmunotherapy for relapsed B-cell non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2013, 88, 589-593.	4.1	33
157	IPI24: An International Study To Create An IPI For The Event-Free Survival At 24 Months (EFS24) Endpoint For DLBCL In The Immunochemotherapy Era. <i>Blood</i> , 2013, 122, 362-362.	1.4	2
158	PET Compared With CT As a Prognosticator After Rituximab Induction Therapy In Follicular Lymphoma: Report From The National Lymphocare Study. <i>Blood</i> , 2013, 122, 4245-4245.	1.4	1
159	Early Relapse Of Follicular Lymphoma After R-CHOP Uniquely Defines Patients At High Risk For Death: An Analysis From The National Lymphocare Study. <i>Blood</i> , 2013, 122, 510-510.	1.4	5
160	Identification of Candidate B-Lymphoma Genes by Cross-Species Gene Expression Profiling. <i>PLoS ONE</i> , 2013, 8, e76889.	2.5	13
161	Shroom3, a novel GWAS renal candidate, is essential for glomerular barrier function. <i>FASEB Journal</i> , 2013, 27, 955.6.	0.5	0
162	Elevated Soluble IL-2Ra Levels Are Associated With Inferior Outcome and Is Independent Of MIPI Score in Patients With Mantle Cell Lymphoma. <i>Blood</i> , 2013, 122, 4256-4256.	1.4	0

#	ARTICLE	IF	CITATIONS
163	A Genome-Wide Association Study (GWAS) Of Event-Free Survival In Diffuse Large B-Cell Lymphoma (DLBCL) Treated With Rituximab and Anthracycline-Based Chemotherapy: A Lysa and Iowa/Mayo Clinic SPORE Multistage Study. <i>Blood</i> , 2013, 122, 76-76.	1.4	1
164	Variability Of Performance Status Assessment Between Patients With Hematologic Malignancies and Their Physicians. <i>Blood</i> , 2013, 122, 1703-1703.	1.4	0
165	Complement Factor H Related Protein 1 (CFHR1) Serum Level Correlates With Event-Free Survival In Follicular Lymphoma Patients Treated With Rituximab. <i>Blood</i> , 2013, 122, 4288-4288.	1.4	0
166	Tumor Monocyte Cross Talk Promotes Chemotherapy Resistance In Lymphoma. <i>Blood</i> , 2013, 122, 1774-1774.	1.4	0
167	A Proposed Prognostic Model For Overall Survival In The Oldest Old (>80 Years Old) Follicular Lymphoma Patients. <i>Blood</i> , 2013, 122, 3058-3058.	1.4	0
168	A Meta-Analysis Of Hodgkin Lymphoma Reveals 19p13.3 (TCF3) As a Novel Susceptibility Loc. <i>Blood</i> , 2013, 122, 626-626.	1.4	0
169	Population-Based Exploration of Academic Achievement Outcomes in Pediatric Acute Lymphoblastic Leukemia Survivors. <i>Journal of Pediatric Psychology</i> , 2012, 37, 458-466.	2.1	21
170	Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 3879-3884.	7.1	853
171	Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγR1IIa-Genotyped Patients with Previously Treated Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2012, 18, 1395-1403.	7.0	61
172	Chemo-immunotherapy dosing in older patients with diffuse large B-cell lymphoma: is this how we should treat our parents?. <i>Leukemia and Lymphoma</i> , 2012, 53, 1435-1436.	1.3	2
173	Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 211-217.	1.3	82
174	Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 3368-3375.	1.6	154
175	Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. <i>Blood</i> , 2012, 119, 3698-3704.	1.4	125
176	Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. <i>Blood</i> , 2012, 119, 4129-4132.	1.4	67
177	A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32. <i>Blood</i> , 2012, 119, 469-475.	1.4	66
178	Common variants within 6p21.31 locus are associated with chronic lymphocytic leukaemia and, potentially, other non-Hodgkin lymphoma subtypes. <i>British Journal of Haematology</i> , 2012, 159, n/a-n/a.	2.5	13
179	Pretreatment circulating serum cytokines associated with follicular and diffuse large B-cell lymphoma: A clinic-based case-control study. <i>Cytokine</i> , 2012, 60, 882-889.	3.2	50
180	A systematic review of validated methods for identifying lymphoma using administrative data. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 203-212.	1.9	21

#	ARTICLE	IF	CITATIONS
181	Elevated pretreatment serum levels of interferon-inducible protein 10 (CXCL10) predict disease relapse and prognosis in diffuse large B-cell lymphoma patients. <i>American Journal of Hematology</i> , 2012, 87, 865-869.	4.1	37
182	Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 880-885.	4.1	36
183	Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States. <i>Cancer</i> , 2012, 118, 4842-4850.	4.1	40
184	Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population. <i>Blood</i> , 2012, 120, 1540-1540.	1.4	2
185	Rates and Outcomes of Follicular Lymphoma Transformation in the Rituximab Era: A Report From the University of Iowa/Mayo Clinic SPORE Molecular Epidemiology Resource. <i>Blood</i> , 2012, 120, 1546-1546.	1.4	1
186	Age Differences in Disease Characteristics, Patterns of Care, and Outcomes of Follicular Lymphoma (FL) in the United States (US): Report From the National Lymphocare Study (NLCS). <i>Blood</i> , 2012, 120, 3708-3708.	1.4	4
187	Patterns of Delivery of Chemoimmunotherapy to Patients with Follicular Lymphoma in the United States: Results of the National Lymphocare Study. <i>Blood</i> , 2012, 120, 3702-3702.	1.4	0
188	Anti-Tumor Activity of Low Dose Ocaratuzumab in Previously Treated Follicular Lymphoma Patients with Low-Affinity CD16 Polymorphisms. <i>Blood</i> , 2012, 120, 4884-4884.	1.4	0
189	EBV(+) Diffuse Large B Cell Lymphoma Is Infrequent in Upper Central United States and Lacks Unique Clinical Characteristics or Adverse Prognosis Compared to EBV (âˆ“) Counterparts: Results From University of Iowa/Mayo Clinic SPORE. <i>Blood</i> , 2012, 120, 1604-1604.	1.4	1
190	Impact of Obesity and Genetic Variation in Energy Balance and Metabolism Genes On Prognosis in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). <i>Blood</i> , 2012, 120, 684-684.	1.4	0
191	Germline Genetic Variation and Risk of Follicular Lymphoma Transformation in the Modern Treatment Era. <i>Blood</i> , 2012, 120, 149-149.	1.4	0
192	Non-Follicular Low Grade B-Cell Lymphomas: Patterns of Presentation and Management with Comparative Prognostic Utility of IPI and FLIPI. <i>Blood</i> , 2012, 120, 1563-1563.	1.4	0
193	Prognostic Value of Six Germline Single Nucleotide Polymorphisms At the REL, HLA-DRA, GATA3 and PVT1 Loci Identified in a Classical Hodgkin Lymphoma Genome-Wide Association Study: A Meta-Analysis of 601 Patients for Progression-Free Survival From Two Independent Studies. <i>Blood</i> , 2012, 120, 3637-3637.	1.4	0
194	CXCR5 Polymorphisms in Non-Hodgkin Lymphoma (NHL) Risk and Prognosis.. <i>Blood</i> , 2012, 120, 2702-2702.	1.4	0
195	Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2011, 11, 443-455.	2.4	3
196	Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 4053-4061.	1.4	136
197	Reappraisal of the provisional entity primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma: A series of 10 adult and pediatric patients and review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2011, 65, 739-748.	1.2	66
198	Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 1492-1498.	1.4	110

#	ARTICLE	IF	CITATIONS
199	Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. <i>Blood</i> , 2011, 117, 1911-1916.	1.4	118
200	Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. <i>Blood</i> , 2011, 118, 4882-4889.	1.4	37
201	Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 2821-2826.	1.4	50
202	Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. <i>Blood</i> , 2011, 118, 3347-3349.	1.4	117
203	Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. <i>Leukemia and Lymphoma</i> , 2011, 52, 994-1002.	1.3	50
204	Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2011, 86, 998-1000.	4.1	28
205	Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma. <i>Advances in Hematology</i> , 2011, 2011, 1-7.	1.0	5
206	Elevated Serum Free Light Chains Are Associated With Event-Free and Overall Survival in Two Independent Cohorts of Patients With Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 1620-1626.	1.6	70
207	A Comparison of the Effectiveness of First-Line Chemoimmunotherapy Regimens for Follicular Lymphoma (FL) Used in the United States. <i>Blood</i> , 2011, 118, 97-97.	1.4	10
208	Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101. <i>Journal of Clinical Oncology</i> , 2010, 28, 4500-4506.	1.6	71
209	Cyclophosphamide, Vincristine, and Prednisone Followed by Tositumomab and Iodine-131â€“Tositumomab in Patients With Untreated Low-Grade Follicular Lymphoma: Eight-Year Follow-Up of a Multicenter Phase II Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3035-3041.	1.6	54
210	Vitamin D Insufficiency and Prognosis in Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4191-4198.	1.6	184
211	18-Fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of â€“indeterminateâ€™ reports. <i>Leukemia and Lymphoma</i> , 2010, 51, 439-446.	1.3	21
212	Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 975-983.	1.2	90
213	Phase I Clinical Trial of an Adenovirus/Prostate-Specific Antigen Vaccine for Prostate Cancer: Safety and Immunologic Results. <i>Clinical Cancer Research</i> , 2009, 15, 7375-7380.	7.0	79
214	Measuring Granulocyte and Monocyte Accumulation at Malignant Lymphoma Sites. <i>Journal of Clinical Oncology</i> , 2009, 27, 154-155.	1.6	3
215	Follicular Lymphoma in the United States: First Report of the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 1202-1208.	1.6	263
216	Risk Factors for Early Transformation of Follicular Lymphoma (FL): Report From the National LymphoCare Study (NLCS).. <i>Blood</i> , 2009, 114, 2698-2698.	1.4	5

#	ARTICLE	IF	CITATIONS
217	Imaging Guiding Therapy Development in Lymphoma. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 84, 443-445.	4.7	1
218	Optimizing Chemotherapeutic Strategies for Peripheral T-Cell Lymphomas. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, S180-S186.	1.4	3
219	Monoclonal Antibodies in Lymphoma: The First Decade. <i>Seminars in Hematology</i> , 2008, 45, 71-74.	3.4	8
220	A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following Rituximab Therapy of Follicular Lymphoma. <i>Clinical Cancer Research</i> , 2008, 14, 6697-6703.	7.0	149
221	The mysteries of mantle cell lymphoma—do PET scans provide a clue?. <i>Leukemia and Lymphoma</i> , 2008, 49, 1662-1663.	1.3	2
222	First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. <i>Blood</i> , 2008, 111, 5486-5495.	1.4	247
223	Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non-Hodgkin's Lymphoma. <i>Clinical Cancer Research</i> , 2007, 13, 6168-6174.	7.0	111
224	Do recent reports of prolonged survival in patients with follicular lymphoma suggest that deferral of therapy is no longer justifiable?. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 219-224.	2.3	0
225	Correlates of Treatment Intensity for Initial Management of Follicular Lymphoma (FL) in the United States: Report from the National Lymphocare Study (NLCS).. <i>Blood</i> , 2007, 110, 2612-2612.	1.4	0
226	Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy. <i>Leukemia and Lymphoma</i> , 2006, 47, 657-663.	1.3	16
227	Clinical Protocol: Phase I Study of an Adenovirus/Prostate-Specific Antigen Vaccine in Men with Metastatic Prostate Cancer. <i>Human Gene Therapy</i> , 2006, 17, 220-229.	2.7	19
228	Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. <i>Blood</i> , 2006, 108, 2648-2654.	1.4	215
229	Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma. <i>Journal of Immunotherapy</i> , 2006, 29, 558-568.	2.4	145
230	Population-based Assessment of Hospitalizations for Neutropenia from Chemotherapy in Older Adults with Non-Hodgkin's Lymphoma (United States). <i>Cancer Causes and Control</i> , 2006, 17, 647-654.	1.8	54
231	Oral Tipifarnib (R115777) Has Single Agent Anti-Tumor Activity in Patients with Relapsed Aggressive Non-Hodgkin Lymphoma (NHL): Results of a Phase II Trial in the University of Iowa/Mayo Clinic Lymphoma SPORE (CA97274).. <i>Blood</i> , 2006, 108, 530-530.	1.4	6
232	Effect of Clinical Characteristics on Neutropenia-Related Inpatient Costs Among Newly Diagnosed Non-Hodgkin's Lymphoma Cases During First-Course Chemotherapy. <i>Pharmacotherapy</i> , 2005, 25, 668-675.	2.6	8
233	Improved Survival of Follicular Lymphoma Patients in the United States. <i>Journal of Clinical Oncology</i> , 2005, 23, 5019-5026.	1.6	249
234	Response Assessment of Aggressive Non-Hodgkin's Lymphoma by Integrated International Workshop Criteria and Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography. <i>Journal of Clinical Oncology</i> , 2005, 23, 4652-4661.	1.6	364

#	ARTICLE	IF	CITATIONS
235	Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. <i>Journal of Leukocyte Biology</i> , 2005, 77, 378-387.	3.3	90
236	In Vitro Activity of the Humanized Anti-HLA-DR Antibodies KRN848 and Apolizumab in Non-Hodgkins Lymphoma Cell Lines.. <i>Blood</i> , 2005, 106, 4826-4826.	1.4	1
237	Antibody Therapy of Lymphoma. <i>Advances in Pharmacology</i> , 2004, 51, 229-253.	2.0	8
238	Monoclonal antibody therapy of B cell lymphoma. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 375-385.	3.1	20
239	Optic neuropathy due to anaplastic large cell lymphoma. <i>Seminars in Ophthalmology</i> , 2004, 19, 81-87.	1.6	7
240	99mTc-depreotide tumour uptake in patients with non-Hodgkin's lymphoma. <i>Nuclear Medicine Communications</i> , 2004, 25, 839-843.	1.1	16
241	Incidence of Febrile Neutropenia Is Low and Unrelated to Day 1 Neutrophil Count in Hodgkin's Lymphoma Treated with ABVD.. <i>Blood</i> , 2004, 104, 4590-4590.	1.4	1
242	Post-treatment surveillance of patients with lymphoma treated with curative intent. <i>Seminars in Oncology</i> , 2003, 30, 375-381.	2.2	7
243	Factors Associated with Early Termination of CHOP Therapy and the Impact on Survival among Patients with Chemosensitive Intermediate-Grade Non-Hodgkin's Lymphoma. <i>Cancer Control</i> , 2003, 10, 396-403.	1.8	44
244	Updated Metaanalysis Finds That Interferon- γ Improves Progression-Free and Overall Survival in Low-Grade Non-Hodgkin's Lymphoma When Administered with Chemotherapy That Contains Anthracyclines or Mitoxantrone. <i>Clinical Lymphoma and Myeloma</i> , 2002, 3, 82-84.	2.1	5
245	Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal) Tj ETQq1 1 0.784314 rgBT /Overload	2.2	64
246	Phase II Trial of Remigen (Humanized 1D10) Monoclonal Antibody Targeting Class II in Patients with Relapsed Low-Grade or Follicular Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2001, 2, 188-190.	2.1	26
247	Influences on Oncologists' Adoption of New Agents in Adjuvant Chemotherapy of Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 954-959.	1.6	12
248	CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenström's Macroglobulinemia. <i>Journal of Immunotherapy</i> , 2001, 24, 272-279.	2.4	144
249	Delivering adjuvant chemotherapy to women with early-stage breast carcinoma. <i>Cancer</i> , 2001, 92, 1354-1367.	4.1	91
250	Humanization and characterization of the anti-HLA-DR antibody 1D10. <i>International Journal of Cancer</i> , 2001, 93, 556-565.	5.1	57
251	Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: Safety and Efficacy of Re-Treatment. <i>Journal of Clinical Oncology</i> , 2000, 18, 3135-3143.	1.6	653
252	Anti-CD3-based bispecific antibody designed for therapy of human B-cell malignancy can induce T-cell activation by antigen-dependent and antigen-independent mechanisms. , 1998, 77, 251-256.		27

#	ARTICLE	IF	CITATIONS
253	Monoclonal Antibodies in the Treatment of Human B-Cell Malignancies. <i>Leukemia and Lymphoma</i> , 1998, 31, 237-249.	1.3	14
254	A phase I-II trial of 4'-deoxydoxorubicin (esorubicin) in refractory or relapsed acute leukemia. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 424-428.	4.7	2
255	Cell migration. , 0, , 59-74.		0
256	Long-Term Health-Related Quality of Life of Autologous Hematopoietic Cell Transplantation Patients and Nontransplant Patients With Aggressive Lymphoma: A Prospective Cohort Analysis. <i>JCO Oncology Practice</i> , 0, , .	2.9	0